{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Duration of response will be calculated from the documentation of confirmed response until the date of progression in the subset of patients who respond.","groups":[{"description":"Patients receive anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody (MDX-010) IV over 90 minutes on day 1. Treatment repeats every 28 days for a total of 4 courses in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"MDX-010"}],"populationDescription":"No participants proceeded to Phase 2 for evaluation.","reportingStatus":"POSTED","timeFrame":"From response to progression (up to 2 years)","title":"Duration of Response (Phase 2)","type":"SECONDARY"}